iBio reported earnings of -$ 0.05 per IBIO share on Nov 10, 2026, falling short of analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.07 |
| Earnings Per Share (Surprise) | -$ 0.05 (+$ 0.02) |
| Last Year's EPS | -$ 0.25 |
| EPS YoY Change |
Out of the last 81 earnings reporting periods, iBio beat analysts’ expectations 12 times and fell short of expectations 27 time(s). iBio reported earnings per share of -$ 0.05 in the last report surpassing an estimated EPS of -$ 0.07 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.07 | -$ 0.05 | -$ 0.11 | |
| Aug 28, 2026 | -$ 0.07 | -$ 0.04 | -$ 0.31 | |
| May 12, 2026 | -$ 0.06 | -$ 0.07 | -$ 0.49 | |
| Feb 10, 2026 | -$ 0.08 | -$ 0.09 | -$ 0.48 | |
| Nov 12, 2025 | -$ 0.07 | -$ 0.11 | -$ 0.46 | |
| Sep 5, 2025 | -$ 0.39 | -$ 0.31 | -$ 0.91 | |
| May 2, 2025 | -$ 0.39 | -$ 0.49 | -$ 0.71 | |
| Feb 10, 2025 | -$ 0.45 | -$ 0.48 | -$ 0.71 | |
| Nov 12, 2024 | -$ 0.48 | -$ 0.46 | -$ 2.42 | |
| Sep 25, 2024 | -$ 0.47 | -$ 0.91 | -$ 4.20 | |
| May 14, 2024 | - | -$ 0.71 | -$ 4.20 | |
| May 13, 2024 | - | -$ 0.71 | $ 0.26 | |
| Feb 9, 2024 | -$ 8.20 | -$ 2.42 | -$ 10.80 | |
| Nov 14, 2023 | - | -$ 4.20 | -$ 6.61 | |
| Nov 13, 2023 | - | -$ 4.20 | -$ 21.60 | |
| Sep 27, 2023 | -$ 0.41 | $ 0.26 | -$ 2.05 | |
| May 15, 2023 | -$ 7.20 | -$ 10.80 | -$ 2.05 | |
| May 11, 2023 | -$ 3.42 | -$ 6.61 | -$ 1.96 | |
| Feb 14, 2023 | -$ 146.90 | -$ 21.60 | -$ 30.00 | |
| Nov 23, 2022 | -$ 1.85 | -$ 2.05 | -$ 25.00 |
iBio’s stock was trading at $ 0.795 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, IBIO’s price increased to $ 0.8242 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.05 | $ 0.795 | $ 0.8242 | |
| Aug 28, 2026 | -$ 0.04 | $ 1.40 | $ 1.27 | |
| May 12, 2026 | -$ 0.07 | $ 1.66 | $ 1.55 | |
| Feb 10, 2026 | -$ 0.09 | $ 2.41 | $ 2.21 | |
| Nov 12, 2025 | -$ 0.11 | $ 1.24 | $ 1.15 | |
| Sep 5, 2025 | -$ 0.31 | $ 0.8113 | $ 0.8548 | |
| May 2, 2025 | -$ 0.49 | $ 1.03 | $ 0.98 | |
| Feb 10, 2025 | -$ 0.48 | $ 3.72 | $ 3.17 | |
| Nov 12, 2024 | -$ 0.46 | $ 2.56 | $ 2.32 | |
| Sep 25, 2024 | -$ 0.91 | $ 1.83 | $ 1.95 | |
| May 14, 2024 | -$ 0.71 | $ 1.82 | $ 1.88 | |
| May 13, 2024 | -$ 0.71 | $ 1.85 | $ 1.88 | |
| Feb 9, 2024 | -$ 2.42 | $ 1.15 | $ 1.21 | |
| Nov 14, 2023 | -$ 4.20 | $ 5.80 | $ 5.60 | |
| Nov 13, 2023 | -$ 4.20 | $ 5.60 | $ 5.60 | |
| Sep 27, 2023 | $ 0.26 | $ 6.00 | $ 5.80 | |
| May 15, 2023 | -$ 10.80 | $ 20.20 | $ 18.60 | |
| May 11, 2023 | -$ 6.61 | $ 21.20 | $ 20.20 | |
| Feb 14, 2023 | -$ 21.60 | $ 19.00 | $ 17.00 | |
| Nov 23, 2022 | -$ 2.05 | $ 30.80 | $ 32.60 |
iBio released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
iBio beat analysts’ expectations during the last earnings period by
